Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):285-289. In the adult population, eosinophilic esophagitis tends to be chronic, but stable, with no significant effect on morbidity or mortality.

Eosinophilic esophagitis is now an established cause of dysphagia. Gastroenterologists should have a high clinical suspicion for this condition if the characteristic clinical and endoscopic ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

3Q Loss C$2.66M D-Box Technologies 3Q Rev C$12.1M Discovery Silver 3Q Loss/Shr C$0.01 Eupraxia Pharmaceuticals Announces Positive Data From Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...